The International Federation of Gynaecology and Obstetrics (FIGO) introduced a new staging system for endometrial carcinoma FIGO 2023 in June 2023. The new staging system differs significantly from previous versions by incorporating other non-anatomical parameters (histological type of tumour, tumour grade and the presence of massive lymphovascular space involvement as well as the molecular classification of the tumour). The FIGO 2023 staging system enhances the accuracy of prognostic assessments for patients at a specific stage with better options for targeted treatment. Another objective was to synchronise staging as much as possible with the European oncogynaecological ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma established in 2021. However, several changes are controversial. Routine molecular classification of endometrial carcinomas is not yet commonly available in most countries of the world. Another limitation of the FIGO 2023 staging system of endometrial cancer is the inclusion of variables whose definitions are still evolving, as well as variables that are subject to considerable interobserver variability in their assessment. Advantages, controversies, and limitations for clinical practice of the new FIGO 2023 endometrial cancer staging system are discussed.

Im Juni 2023 hat die Internationale Vereinigung für Gynäkologie und Geburtshilfe (FIGO) ein neues Staging-System für das Endometriumkarzinom – FIGO 2023 – eingeführt. Das neue Staging-System unterscheidet sich signifikant von früheren Versionen, da nun auch andere nicht anatomische Parameter (z. B. histologischer Tumortyp, Tumorgrad, ausgedehnter Befall des lymphatischen Raums sowie die molekulare Klassifikation von Tumoren) einbezogen wurden. Das FIGO-2023-Staging-System verbessert die prognostische Genauigkeit bei Patientinnen in einem bestimmten Tumorstadium mit einer besseren Auswahl an gezielten Behandlungsmöglichkeiten. Zweck des neuen Systems ist es auch, das FIGO-Staging weitmöglichst mit dem Staging der gynäkologisch-onkologischen Europäischen Leitlinien der ESGO/ESTRO/ESP, die im Jahre 2021 für das Management von Patientinnen mit Endometriumkarzinom aufgestellt wurden, in Einklang zu bringen. Allerdings werden mehrere Änderungen immer noch kontrovers diskutiert. So ist in den meisten Ländern der Welt die routinemäßige molekulare Klassifikation von Endometriumkarzinomen nicht allgemein üblich oder erhältlich. Eine weitere Einschränkung des FIGO-2023-Staging-Systems für das Endometriumkarzinom ist die Einbeziehung von Variablen, deren Definitionen noch im Entstehen begriffen sind, bzw. von Variablen, die eine erhebliche Interobserver-Variabilität aufweisen. Die Vorteile, Kontroversen und Einschränkungen des neuen FIGO-2023-Staging-Systems in der klinischen Praxis werden hier diskutiert.

Department of Obstetrics and Gynaecology University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University Prague 10 Czech Republic

Department of Pathology and Molecular Medicine Thomayer University Hospital and 3rd Faculty of Medicine Charles University Prague 4 Czech Republic

Department of Pathology General University Hospital Prague and 1st Faculty of Medicine Charles University Prague 2 Czech Republic

Department of Pathology University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University Prague 10 Czech Republic

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

Cancer Genome Atlas Research Network . Kandoth C, Schultz N, Cherniack AD et al.Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113. PubMed DOI PMC

Stelloo E, Nout RA, Osse EM et al.Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin Cancer Res. 2016;22:4215–4224. doi: 10.1158/1078-0432.CCR-15-2878. PubMed DOI

León-Castillo A, de Boer SM, Powell ME et al.Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020;38:3388–3397. doi: 10.1200/JCO.20.00549. PubMed DOI PMC

Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109. doi: 10.1016/j.ijgo.2009.02.010. PubMed DOI

Berek JS, Matias-Guiu X, Creutzberg C et al.FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162:383–394. doi: 10.1002/ijgo.14923. PubMed DOI

Anglesio MS, Wang YK, Maassen M et al.Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. J Natl Cancer Inst. 2016;108:djv428. doi: 10.1093/jnci/djv428. PubMed DOI

Hájková N, Tichá I, Hojný J et al.Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases. Oncol Lett. 2019;17:2207–2214. doi: 10.3892/ol.2018.9855. PubMed DOI PMC

Schwameis R, Fanfani F, Ebner C et al.Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres. Eur J Cancer. 2023;193:113317. doi: 10.1016/j.ejca.2023.113317. PubMed DOI

Concin N, Matias-Guiu X, Vergote I et al.ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiother Oncol. 2021;154:327–353. doi: 10.1016/j.radonc.2020.11.018. PubMed DOI

Mueller JJ, Pedra Nobre S, Braxton K et al.Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma. Gynecol Oncol. 2020;157:619–623. doi: 10.1016/j.ygyno.2020.03.025. PubMed DOI PMC

Krizova A, Clarke BA, Bernardini MQ et al.Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review. Am J Surg Pathol. 2011;35:115–126. doi: 10.1097/PAS.0b013e31820273dc. PubMed DOI

Burg L, Timmermans M, van der Aa M et al.Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands. J Gynecol Oncol. 2020;31:e58. doi: 10.3802/jgo.2020.31.e58. PubMed DOI PMC

Li H, Zhang R, Chen C et al.Prognostic value of different metastatic sites for patients with FIGO stage IVB endometrial cancer after surgery: A SEER database analysis. J Surg Oncol. 2020;122:941–948. doi: 10.1002/jso.26102. PubMed DOI

Piulats JM, Guerra E, Gil-Martín M et al.Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol. 2017;145:200–207. doi: 10.1016/j.ygyno.2016.12.015. PubMed DOI

McCluggage WG, Bosse T, Gilks CB et al.FIGO 2023 endometrial cancer staging: too much, too soon? Int J Gynecol Cancer. 2024;34:138–143. doi: 10.1136/ijgc-2023-004981. PubMed DOI

WHO Classification of Tumours Editorial Board . Female Genital Tumours. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Female-Genital-Tumours-2020 https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Female-Genital-Tumours-2020

Cree IA, White VA, Indave BI et al.Revising the WHO classification: female genital tract tumours. Histopathology. 2020;76:151–156. doi: 10.1111/his.13977. PubMed DOI

Cui J, Chen X, Zhai Q et al.A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report. Diagn Pathol. 2023;18:19. doi: 10.1186/s13000-023-01287-y. PubMed DOI PMC

Smithgall MC, Remotti H, Hsiao SJ et al.Investigation of discrepant mismatch repair immunohistochemistry and microsatellite instability polymerase chain reaction test results for gynecologic cancers using next-generation sequencing. Hum Pathol. 2022;119:41–50. doi: 10.1016/j.humpath.2021.10.004. PubMed DOI

Köbel M, Ronnett BM, Singh N et al.Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol. 2019;38 1:S123–S131. doi: 10.1097/PGP.0000000000000488. PubMed DOI PMC

Corr B, Cosgrove C, Spinosa D et al.Endometrial cancer: molecular classification and future treatments. BMJ Med. 2022;1:e000152. doi: 10.1136/bmjmed-2022-000152. PubMed DOI PMC

Espinosa I, D’Angelo E, Prat J. Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging. Gynecol Oncol. 2024;186:94–103. doi: 10.1016/j.ygyno.2024.04.008. PubMed DOI

Streel S, Salmon A, Dheur A et al.Diagnostic Performance of Immunohistochemistry Compared to Molecular Techniques for Microsatellite Instability and p53 Mutation Detection in Endometrial Cancer. Int J Mol Sci. 2023;24:4866. doi: 10.3390/ijms24054866. PubMed DOI PMC

Singh N, Piskorz AM, Bosse T et al.p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol. 2020;250:336–345. doi: 10.1002/path.5375. PubMed DOI

Matsumoto N, Manrai P, Rottmann D et al.Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas. Int J Gynecol Pathol. 2023;42:567–575. doi: 10.1097/PGP.0000000000000930. PubMed DOI

Raffone A, Travaglino A, Cerbone M et al.Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer. Pathol Res Pract. 2020;216:153025. doi: 10.1016/j.prp.2020.153025. PubMed DOI

Talhouk A, McConechy MK, Leung S et al.Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123:802–813. doi: 10.1002/cncr.30496. PubMed DOI

León-Castillo A, Gilvazquez E, Nout R et al.Clinicopathological and molecular characterisation of „multiple-classifier“ endometrial carcinomas. J Pathol. 2020;250:312–322. doi: 10.1002/path.5373. PubMed DOI PMC

Visser NCM, van der Wurff AAM, IntHout J et al.Improving preoperative diagnosis in endometrial cancer using systematic morphological assessment and a small immunohistochemical panel. Hum Pathol. 2021;117:68–78. doi: 10.1016/j.humpath.2021.08.006. PubMed DOI

Weinberger V, Bednarikova M, Hausnerova J et al.A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers. Front Oncol. 2019;9:265. doi: 10.3389/fonc.2019.00265. PubMed DOI PMC

Vrede SW, van Weelden WJ, Visser NCM et al.Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecol Oncol. 2021;161:787–794. doi: 10.1016/j.ygyno.2021.03.031. PubMed DOI

Bosse T, Peters EEM, Creutzberg CL et al.Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51:1742–1750. doi: 10.1016/j.ejca.2015.05.015. PubMed DOI

Veade AE, Foote J, Ehrisman J et al.Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma. World J Surg Oncol. 2019;17:80. doi: 10.1186/s12957-019-1620-x. PubMed DOI PMC

Tortorella L, Restaino S, Zannoni GF et al.Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. J Gynecol Oncol. 2021;32:e11. doi: 10.3802/jgo.2021.32.e11. PubMed DOI PMC

Bosse T, Nout RA, McAlpine JN et al.Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol. 2018;42:561–568. doi: 10.1097/PAS.0000000000001020. PubMed DOI PMC

Abu-Rustum N, Yashar C, Arend R et al.Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21:181–209. doi: 10.6004/jnccn.2023.0006. PubMed DOI

Matias-Guiu X, Selinger CI, Anderson L et al.Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR) Int J Gynecol Pathol. 2022;41:S90–S118. doi: 10.1097/PGP.0000000000000901. PubMed DOI

Singh N, Hirschowitz L, Zaino R et al.Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade) Int J Gynecol Pathol. 2019;38 1:S93–S113. doi: 10.1097/PGP.0000000000000524. PubMed DOI PMC

College of American Pathologists . Homepage. https://www.cap.org/ https://www.cap.org/

Emons G, Steiner E, Vordermark D et al.Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures. Geburtshilfe Frauenheilkd. 2023;83:919–962. doi: 10.1055/a-2066-2051. PubMed DOI PMC

Kayraklioglu N, Katsakhyan L, Cohen PA et al.Perceptions of Controversies and Unresolved Issues in the 2014 FIGO Staging System for Endometrial Cancer: Survey Results From Members of the International Society of Gynecological Pathologists and International Gynecologic Cancer Society. Int J Gynecol Pathol. 2024;43:242–252. doi: 10.1097/PGP.0000000000000977. PubMed DOI

Betella I, De Vitis LA, Calidona C et al.Letter to the editor-The new FIGO staging system for endometrial cancer: Is the paradigm shift clinically feasible? Int J Gynaecol Obstet. 2024;164:364–365. doi: 10.1002/ijgo.15265. PubMed DOI

Amin MB, Greene FL, Edge SB et al.The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–99. doi: 10.3322/caac.21388. PubMed DOI

Emons G, Steiner E, Vordermark D et al.Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022) – Part 2 with Recommendations on the Therapy of Precancerous Lesions and Early-stage Endometrial Cancer, Surgical Therapy, Radiotherapy and Drug-based Therapy, Follow-up Care, Recurrence and Metastases, Psycho-oncological Care, Palliative Care, Patient Education, and Rehabilitative and Physiotherapeutic Care. Geburtshilfe Frauenheilkd. 2023;83:963–995. doi: 10.1055/a-2066-2068. PubMed DOI PMC

Mirza MR, Chase DM, Slomovitz BM et al.Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388:2145–2158. doi: 10.1056/NEJMoa2216334. PubMed DOI

Eskander RN, Sill MW, Beffa L et al.Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388:2159–2170. doi: 10.1056/NEJMoa2302312. PubMed DOI PMC

Colombo N, Biagioli E, Harano K et al.Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25:1135–1146. doi: 10.1016/S1470-2045(24)00334-6. PubMed DOI

Westin SN, Moore K, Chon HS et al.Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024;42:283–299. doi: 10.1200/JCO.23.02132. PubMed DOI PMC

Bednaříková M, Hausnerová J, Minář L et al.Molecular testing of endometrial carcinoma in real-world clinical practice. Klin Onkol. 2023;36:215–223. doi: 10.48095/ccko2023215. PubMed DOI

Michalová K, Presl J, Straková-Peteříková A et al.Advantages of next-generation sequencing (NGS) in the molecular classification of endometrial carcinomas – our experience with 270 cases. Ceska Gynekol. 2024;89:349–359. doi: 10.48095/cccg2024349. PubMed DOI

Jamieson A, Huvila J, Chiu D et al.Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. Mod Pathol. 2023;36:100085. doi: 10.1016/j.modpat.2022.100085. PubMed DOI

Vermij L, Jobsen JJ, León-Castillo A et al.Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry. Br J Cancer. 2023;128:1360–1368. doi: 10.1038/s41416-023-02141-0. PubMed DOI PMC

De Vitis LA, Schivardi G, Caruso G et al.Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review. Int J Gynecol Cancer. 2024;34:229–238. doi: 10.1136/ijgc-2023-004864. PubMed DOI

Zhan X, Li L, Wu M et al.The prognosis of stage IA synchronous endometrial endometrioid and ovarian carcinomas. Arch Gynecol Obstet. 2019;300:1045–1052. doi: 10.1007/s00404-019-05288-5. PubMed DOI PMC

Turashvili G, Gómez-Hidalgo NR, Flynn J et al.Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecol Oncol. 2019;152:38–45. doi: 10.1016/j.ygyno.2018.10.033. PubMed DOI PMC

Assem H, Rottmann D, Finkelstein A et al.Minimal uterine serous carcinoma and endometrial polyp: a close clinicopathological relationship. Hum Pathol. 2021;118:1–8. doi: 10.1016/j.humpath.2021.09.001. PubMed DOI

Brych O, Drozenová J, Pichlík T et al.Preoperative and postoperative staging in endometrial cancer – a prospective study. Ceska Gynekol. 2024;89:5–10. doi: 10.48095/cccg20245. PubMed DOI

Michal M, Valha P, Velemínský M. Sentinel lymph node mapping in endometrial cancer – robotic vs. laparoscopic detection system. Ceska Gynekol. 2023;88:157–161. doi: 10.48095/cccg2023157. PubMed DOI

Vinklerová P, Minář L, Weinberger V et al.Change in the trend of surgical treatment and staging of lymph nodes in endometrial cancer – results of the Oncogynecology Center, Department of Gynecology and Obstetrics, University Hospital Brno and Masaryk University in the years 2012–2021. Ceska Gynekol. 2022;87:308–316. doi: 10.48095/cccg2022308. PubMed DOI